Search results
Showing 961 to 975 of 1308 results for social care
In development Reference number: GID-TA11567 Expected publication date: TBC
The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)
NICE has developed a Medtech Innovation Briefing (MIB) on the ARROW OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy
Rapid tests for group A streptococcal infections in people with a sore throat (HTG531)
Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat.
Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on the Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult .
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
supporting family members, carers and staffto be resilient and able to provide care and support to people with a learning disability and...
NICE has developed a medtech innovation briefing (MIB) on DuraGraft for preserving vascular grafts .
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Holoclar for treating limbal stem cell deficiency after eye burns (TA467)
Evidence-based recommendations on Holoclar (a layer of cells grown from cells taken from your own eye) for treating limbal stem cell deficiency in adults with eye burns.
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.
Pegzilarginase for treating arginase-1 deficiency in people 2 years and over (HST35)
Evidence-based recommendations on pegzilarginase (Loargys) for treating arginase-1 deficiency in people 2 years and over.
Show all sections
CG173/4 Question What are the key factors, including additional care and support, that influence participation* and quality of life in...
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
GID-MT563 NPi-200 for pupillary light reflex in critical care patients
Discontinued Reference number: GID-MT563